See the DrugPatentWatch profile for repatha
Does Repatha Lower Cholesterol?
Yes, Repatha (evolocumab) lowers LDL cholesterol, the "bad" type linked to heart disease. It's a PCSK9 inhibitor that blocks a protein reducing the liver's ability to clear LDL from blood. Clinical trials show it cuts LDL by 50-70% when added to statins or used alone in statin-intolerant patients.[1][2]
How Does Repatha Work?
Repatha binds PCSK9, allowing more LDL receptors on liver cells to pull LDL from circulation. In the FOURIER trial, patients on Repatha plus statins saw LDL drop from 92 mg/dL to 30 mg/dL on average, reducing major cardiovascular events by 20%.[1] It's injected every two weeks or monthly.
Who Gets Prescribed Repatha?
Doctors prescribe it for:
- Adults with high LDL despite max statin doses, especially with heart disease.
- Kids 10+ with familial hypercholesterolemia (FH), a genetic high-cholesterol condition.
- Those with atherosclerotic cardiovascular disease needing extra LDL reduction.[2]
It doesn't replace statins but boosts them.
Repatha vs. Statins or Other Options
| Treatment | LDL Reduction | Common Use | Key Difference |
|-----------|---------------|------------|---------------|
| Repatha | 50-70% | Add-on to statins | Targets PCSK9; self-injectable |
| Statins (e.g., atorvastatin) | 20-60% | First-line | Oral pill; broader availability |
| Praluent (alirocumab) | 50-65% | Similar to Repatha | Another PCSK9 inhibitor; slightly different dosing |
| Inclisiran | 40-50% | Twice-yearly injection | RNA-based; fewer doses |
Repatha outperforms statins alone in high-risk cases but costs more (~$5,000-$6,000/year before insurance).[3]
Side Effects and Patient Concerns
Common: Injection-site reactions (bruising, pain), flu-like symptoms, back pain. Rare: Allergic reactions, high blood pressure. No major liver or muscle risks like statins. Patients report easier adherence than daily pills but note high copays.[2][4]
Cost, Access, and Patent Timeline
List price is $5,850 for two months' supply. Patents expire around 2030-2034 in the US, with challenges ongoing; biosimilars unlikely before then.[5] Insurance often covers for high-risk patients; patient assistance programs exist via Amgen.
[1] NEJM: FOURIER Trial (2017) - https://www.nejm.org/doi/full/10.1056/NEJMoa1706445
[2] Repatha Prescribing Information - https://www.repatha.com
[3] GoodRx Pricing Data (2023) - https://www.goodrx.com/repatha
[4] FDA Label - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125522s029lbl.pdf
[5] DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/REPATHA